Present and future of parkinson's disease in Spain : Parkinson-2030 delphi project
Santos García, Diego (Department of Neurology. CHUAC (Complexo Universitario de A Coruña))
Blázquez Estrada, Marta (Hospital Universitario Central de Asturias)
Calopa, Matilde (Hospital Universitari de Bellvitge)
Escamilla Sevilla, Francisco (Instituto de Investigación Sanitaria de Granada)
Freire, Eric (Departamento de Neurología. Hospital IMED Elche)
García Ruiz, Pedro J. (Servicio de Neurología. Fundación Jiménez Díaz)
Grandas, Francisco (Hospital General Universitario Gregorio Marañón)
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau)
López Manzanares, Lydia (Hospital Universitario de la Princesa (Madrid))
Martínez-Castrillo, Juan Carlos (Hospital Universitario Ramón y Cajal (Madrid))
Mir, Pablo (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau)
Pérez-Errazquin, Francisco (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Salom, José María (Hospital Clínic Universitari (València))
Tijero, Beatriz (Hospital Universitario de Cruces (Barakaldo, País Basc))
Valldeoriola, Francesc (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Yáñez, Rosa (Servicio de Neurología. Complejo Hospitalario Univ. Ourense)
Avilés, Arantxa (Departamento Médico. Zambon S.A.U)
Luquin, Maria-Rosario (Instituto de Investigación Sanitaria de Navarra)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120. 000-150. 000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on pa-tients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. Accord-ing to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
Note:	Altres ajuts: Zambon S.A.U.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Diagnosis ; Economic impact ; Epidemiology ; Management ; Mortality ; Parkinson's disease ; Quality of life ; Spain ; Treatment
Published in:	Brain sciences, Vol. 11 Núm. 8 (august 2021) , p. 1027, ISSN 2076-3425

DOI: 10.3390/brainsci11081027
PMID: 34439646

18 p, 1.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles